R&D investment
Sales Revenue
R&D investment ratio: 10%
R & D personnel≥19%
Masters & Ph.D Employees Ratio: ≥13%

Pioneering in Molecular Diagnostic, BioPerfectus has clinically approved and internationally recognized core technology platforms including multiple quantitative PCR, nucleic acid extraction solutions and rapid test.BioPerfectus possess ISO13485 international quality standards for production; well sterilized and high safety PCR laboratories to research and develop products.Over 500 products, 41 patents, 16 software copyrights and more than 70 NMPA registration certificates, our products have received the good recommendation and recognition from home and abroad.

> 500




> 70

Registration Certificates


Software Copyrights

Quality Commitments
BioPerfectus believes that the quality of a business's product and service is in direct proportion to its commitment to excellence.
Technical Platforms
Nucleic Acid Extraction Platform: Automated device which integrates new technologies such as machine, electricity, software and pre-packed reagents to enable automatic nucleic acid extraction of various samples.
Multiplex Real-time PCR Platform: Multiplex fluorescence quantitative PCR, digital PCR, which will enable to detect infectious diseases, obstetrics and gynecology, pediatrics, tumors and so on.
Protein Detection Platform: ELISA, enzyme chemistry, lateral flow, immunofluorescence technologies and so on.
Raw Material Support Platform: Enzymes, proteins, antigens, antibodies, various extraction reagents.
Solution Centers

Smart Laboratory Solutions

Specimen Analysis Solutions

Specimen Pretreatment Solutions

Vaginal Micro-ecology Evaluation System

R&D Partnership